MONROL
Following an ongoing assessment of its entire operation, Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has decided to establish a legal entity and manufacturing facility in Germany.
The new facility will focus on the manufacture of SPECT products and radiopharmaceutical products for radioligand therapy(*) such as Gallium-68 generator and n.c.a Lutetium-177. Developed by Monrol R&D teams, these products are widely used in the production of radiopharmaceuticals for cancer patients. The facility will also have a dedicated division for state-of-the art cGMP Contract Development and Manufacturing Organization (CDMO) services.
Monrol plans to make the site a center of excellence for both radiopharmaceutical production and scientific and industry collaborative efforts to create innovations. The facility is expected to be up and running by 2026 at an estimated cost of around 30 million euros.
(*) Targeted radioligand therapy is an innovative approach to cancer treatment that is considered to be one of the most remarkable and advanced therapies currently under study. Multiple clinical development programs and clinical trials around the world are testing this approach for various cancer types.
About Lutetium-177 n.c.a
Lutetium-177 n.c.a is a radioisotope of choice for targeted radionuclide therapy. Lu-177 n.c.a production process enables treatment options that have the potential to improve treatment outcomes for certain cancer patients. Unique properties of Lutetium-177 n.c.a make it a theranostically desirable radioisotope for peptide receptor radionuclide therapy (PRRT) to treat certain cancers like neuro endocrine tumors (NET) and prostate cancer; many clinical development programs are also testing the therapy for other cancers like ccRCC.
About Gallium-68
A gallium-68 generator is a device used to extract the positron-emitting isotope 68Ga of gallium from decaying germanium-68. The parent isotope 68Ge is easily utilized for in-hospital production of generator-produced 68Ga. Its decay product gallium-68 is extracted and employed in certain positron emission tomography nuclear medicine diagnostic procedures used for the diagnosis of cancer patients and direct tumor imaging.
About Monrol
Monrol is one of the world’s largest nuclear medicine companies and a leader in the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals. The company distributes its own portfolio of world-class radiopharmaceutical products to more than 50 countries around the globe from its headquarters in Istanbul. Committed to transforming and improving patient journeys in cancer treatment, Monrol also provides early development support to CDMO customers as well as fully integrated services for taking new product concepts into clinical trials, demonstrating proof of concept, and moving into first-in-human studies. Located near a major international airport and transportation hub, Monrol benefits from a worldwide logistics network and agreements with cargo services to 320 destinations worldwide. To learn more, visit www.monrol.com and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220928005666/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Survey of Nearly 4,300 C-suite Leaders Reveals Intensifying Demand for Faster Innovation, Higher ROI and Stronger Business Resilience16.12.2025 15:00:00 CET | Press release
Executives face growing pressure to deliver AI-driven transformation while navigating rising costs, increasing risk and shortages in skilled IT talent Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the findings of its new global survey, “C-suite Imperatives: Accelerating Innovation in a Shifting Landscape.” The research was conducted in partnership with Censuswide surveying nearly 4,300 CFOs, CIOs, CEOs and CISOs across the globe, examining the pressures influencing executive-level technology decisions and the priorities shaping their investment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216456670/en/ New Survey of Nearly 4,300 C-suite Leaders Reveals Intensifying Demand for Faster Innovation, Higher ROI
Enersense Selects Sitetracker as the Platform of Choice for 5G and Fiber Expansion Initiatives16.12.2025 15:00:00 CET | Press release
Sitetracker, the global leader in complete Asset Lifecycle Management, announced that Enersense, a leading lifecycle partner for customers operating in energy transmission and production, industrial energy transition and telecommunications services across Finland and the Baltics, has selected Sitetracker to digitize and scale its operations. The implementation enabled Enersense to replace legacy systems, standardize workflows, and support their ability to deliver services with short lead times and high process precision. The first phase of implementation is already supporting Finland’s 5G and rapidly expanding fiber-to-the-home (FTTH) initiatives. Before Sitetracker, Enersense relied on spreadsheets and email to manage project execution, resulting in limited visibility into project milestones, asset tracking, and field performance. As 5G and FTTH deployment accelerated, these manual processes created operational bottlenecks, slowed invoicing, and hindered communication with customers a
Sutherland and ComplyAdvantage Launch AI-Native "Unified FinCrime Compliance" Solution to Combat Sophisticated, Next Generation Financial Crime16.12.2025 15:00:00 CET | Press release
New partnership merges Sutherland’s AI-native FinCrime expertise with ComplyAdvantage’s Mesh Risk Intelligence to deliver an integrated, modular AI-powered ecosystem for Fraud, AML, Risk and Transaction Monitoring. Sutherland, a global leader in business and digital transformation, today announced a strategic partnership with ComplyAdvantage, a leading AI-driven risk intelligence platform. The collaboration introduces a comprehensive, AI-driven financial crime (FinCrime) management solution designed to help banks and Fintechs respond to the rapid rise of AI-designed fraud, complex AML risks, fast-evolving financial crime threats, and complex compliance requirements. Today, financial crime requires sophisticated, AI-intelligence-based solutions, as traditional risk and compliance controls cannot keep up. The Sutherland-ComplyAdvantage solution transforms FinCrime management by delivering a single AI-native intelligence layer that continuously enhances screening, transaction monitoring,
Mastering Complexity & Increasing Efficiency: CES 2026: dSPACE Demonstrates Test and AI Solutions for SDV Development16.12.2025 14:02:00 CET | Press release
At CES 2026, dSPACE will showcase end-to-end test solutions that enable vehicle manufacturers to efficiently master the increasing complexity in the development of software-defined vehicles. At booth 4500 in West Hall, dSPACE will present a comprehensive validation portfolio with AI-supported software-in-the-loop and hardware-in-the-loop solutions for accelerated vehicle development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216117958/en/ At CES 2026, dSPACE will present a comprehensive validation portfolio with AI-supported software-in-the-loop and hardware-in-the-loop solutions for accelerated SDV development. AI is a strategic enabler throughout the entire development and test process. dSPACE has been exploring how the latest developments in generative and agentic AI technologies can support software-in-the-loop (SIL) testing and enable CI/CD pipelines for automated validation. In an exhibit, dSPACE will demonstra
PPG achieves REDCert² sustainable raw material certification at two key European sites16.12.2025 14:01:00 CET | Press release
PPG (NYSE: PPG) today announced that its Architectural Coatings manufacturing sites in Amsterdam, the Netherlands and Søborg, Denmark have received REDCert² certification, which verifies the use of sustainable raw materials through a certified chain of custody. REDCert² uses the mass balance approach, a recognized method for attributing the sustainability value of certified inputs. This ensures that PPG’s products reflect responsible sourcing throughout the manufacturing process and reinforces the company’s commitment to delivering high-performing, sustainably advantaged solutions to customers across Europe. “This certification supports our broader goal of integrating sustainability and productivity into our operations and our commitment to transparent manufacturing,” said Mats Hagerstrom, PPG head of sustainability, EMEA, Architectural Coatings. “It helps us deliver products that meet high performance standards while supporting our customers’ environmental objectives.” The certified s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom